Sign in
FNCH Stock Price, Chart, Stats & News
Finch Therapeutics Group, Inc.
Save
–
Market cap
–
Current P/E
–
Forward P/E
FNCH chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -27.89% |
ROE | -86.83% |
D/E | 3.06x |
Interest coverage ratio | – |
FNCH valuation
P/E | – |
P/S | – |
P/B | 1.63x |
P/CF | -0.47x |
P/FCF | -0.47x |
P/OCF | -0.47x |
PEG | -0.01x |
EV multiple | 0.20x |
About
Finch Therapeutics Group, Inc. is a U. S.-based, clinical-stage biotechnology company dedicated to developing innovative, orally administered biological drugs that leverage the microbiome. Its leading investigational therapy, CP101, is an orally delivered microbiome capsule currently in Phase 3 clinical trials.
Similar securities
Based on sector and market capitalization
Report issue